Literature DB >> 11920621

BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines.

Maria Lourdes De Leon Matsuda1, Alexander Liede, Elaine Kwan, Cynthia A Mapua, Eva Maria C Cutiongco, Alex Tan, Ake Borg, Steven A Narod.   

Abstract

Age-adjusted incidence rates of breast cancer vary more than 10-fold worldwide, with the highest rates reported in North America and Europe. The highest breast cancer incidence rates in Southeast Asia have been reported for the Manila Cancer Registry in the Philippines, with an age-standardized rate of 47.7 per 100,000 per year. The possible contribution of hereditary factors to these elevated rates has not been investigated. We conducted a case-control study of 294 unselected incident breast cancer cases and 346 female controls from Manila, Philippines. Cases and controls were selected from women below the age of 65 undergoing evaluation at the PGH in Manila because of a suspicious breast mass. Molecular analysis identified 12 BRCA2 mutations and 3 BRCA1 mutations. We estimate the prevalence of BRCA mutations among unselected breast cancer cases in the Philippines to be 5.1% (95% CI: 2.6-7.6%), with a prevalence of 4.1% (95% CI: 1.8-6.4%) for BRCA2 mutations alone. The BRCA2 4265delCT and 4859delA mutations were found in 2 and 4 unrelated cases, respectively; haplotype analysis confirmed that these, and the BRCA1 5454delC mutation, are founder mutations. BRCA2 mutations were also found in 2 of 346 controls (0.6%; 95% CI: 0.2-1.4%). Compared with non-carrier cases, the cumulative risk of breast cancer for first-degree relatives of mutation carriers was 24.3% to age 50, compared with <4% for first-degree relatives of non-carrier cases (RR = 6.6; 95% CI: 2.6-17.2; p= 7.5 x 10(-6)). Our data suggest that penetrance of BRCA mutations is not reduced in the Philippines. Germline mutations in the BRCA2 gene contribute more than mutations BRCA1 to breast cancer in the Philippines, due in large part to the presence of 2 common founder mutations. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920621     DOI: 10.1002/ijc.10194

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

Review 2.  Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.

Authors:  Ava Kwong; Vivian Y Shin; John C W Ho; Eunyoung Kang; Seigo Nakamura; Soo-Hwang Teo; Ann S G Lee; Jen-Hwei Sng; Ophira M Ginsburg; Allison W Kurian; Jeffrey N Weitzel; Man-Ting Siu; Fian B F Law; Tsun-Leung Chan; Steven A Narod; James M Ford; Edmond S K Ma; Sung-Won Kim
Journal:  J Med Genet       Date:  2015-07-17       Impact factor: 6.318

3.  Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.

Authors:  Safinaz S Ibrahim; Elsayed E Hafez; Mervat M Hashishe
Journal:  J Exp Clin Cancer Res       Date:  2010-06-25

4.  Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.

Authors:  Bifeng Zhang; James D Fackenthal; Qun Niu; Dezheng Huo; Walmy E Sveen; Tiffani DeMarco; Clement A Adebamowo; Temidayo Ogundiran; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

5.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Authors:  Ophira M Ginsburg; Mohammad R Akbari; Zeba Aziz; Robert Young; Henry Lynch; Parviz Ghadirian; Andre Robidoux; Julian Londono; Gonzalo Vasquez; Magda Gomes; Mauricio Magalhaes Costa; Constantine Dimitrakakis; Gustavo Gutierrez; Robert Pilarski; Robert Royer; Steven A Narod
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

6.  Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.

Authors:  Cheng-Har Yip; N A Taib; W Y Choo; S Rampal; M K Thong; S H Teo
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

7.  Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers.

Authors:  Julia Fehniger; Feng Lin; Mary S Beattie; Galen Joseph; Celia Kaplan
Journal:  J Genet Couns       Date:  2013-05-12       Impact factor: 2.537

8.  Performance of BRCA1/2 mutation prediction models in Asian Americans.

Authors:  Allison W Kurian; Gail D Gong; Nicolette M Chun; Meredith A Mills; Ashley D Staton; Kerry E Kingham; Beth B Crawford; Robin Lee; Salina Chan; Susan S Donlon; Yolanda Ridge; Karen Panabaker; Dee W West; Alice S Whittemore; James M Ford
Journal:  J Clin Oncol       Date:  2008-09-08       Impact factor: 44.544

Review 9.  Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.

Authors:  Carlos Andrés Ossa; Diana Torres
Journal:  Oncologist       Date:  2016-06-10

10.  Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients.

Authors:  Sei Hyun Ahn; Ui Kang Hwang; Beom Seok Kwak; Ho Sung Yoon; Bo Kyung Ku; Hee Jun Kang; Ji Su Kim; Byung Kyun Ko; Chang Dae Ko; Kyung Sik Yoon; Dae-Yeon Cho; Jun Suk Kim; Byung Ho Son
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.